HALO Halozyme Therapeutics Incorporated

-0.06 (-0.16%)
Last Updated: 14:21:12
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 413,688
Bid Price 38.41
Ask Price 38.43
News -
Day High 39.26


52 Week Range


Day Low 38.23
Company Name Stock Ticker Symbol Market Type
Halozyme Therapeutics Incorporated HALO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.06 -0.16% 38.41 14:21:12
Open Price Low Price High Price Close Price Prev Close
38.51 38.23 39.26 38.47
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
8,099 413,688 $ 38.61 $ 15,972,415 - 29.85 - 59.46
Last Trade Time Type Quantity Stock Price Currency
14:21:49 2 $ 38.415 USD

Halozyme Therapeutics (HALO) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


Halozyme Therapeutics Incorporated Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
5.07B 131.92M - 660.12M 202.13M 1.53 25.06
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Halozyme Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No HALO Message Board. Create One! See More Posts on HALO Message Board See More Message Board Posts

Historical HALO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week39.7740.5438.1439.27696,534-1.36-3.42%
1 Month43.0743.3337.4339.84930,159-4.66-10.82%
3 Months36.8545.0035.7141.09989,6461.564.23%
6 Months34.7945.0029.8537.221,137,8303.6210.41%
1 Year39.0759.4629.8543.041,240,446-0.66-1.69%
3 Years26.1259.4625.6941.681,188,90012.2947.05%
5 Years17.9259.4612.7133.091,157,03520.49114.34%

Halozyme Therapeutics Description

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.